Active	Status	Sponsor type	Region	Phase	Filter
9 Active 5 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Schneider, Lon
NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease	Active, not recruiting	2/3	225	Canada, US	Piromelatine 20 mg, Neu-P11, Placebo	Neurim Pharmaceuticals Ltd., Syneos Health	Alzheimer's Disease	06/25	06/25
Nand, Cheta
NCT01908192 / 2017-001168-39: Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®	Terminated	2/3	60	US, RoW	NaBen®, Placebo	SyneuRx International (Taiwan) Corp	Schizophrenia	10/23	10/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Schneider, Lon
NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease	Active, not recruiting	2/3	225	Canada, US	Piromelatine 20 mg, Neu-P11, Placebo	Neurim Pharmaceuticals Ltd., Syneos Health	Alzheimer's Disease	06/25	06/25
Nand, Cheta
NCT01908192 / 2017-001168-39: Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®	Terminated	2/3	60	US, RoW	NaBen®, Placebo	SyneuRx International (Taiwan) Corp	Schizophrenia	10/23	10/23